Alpha 2.0
Login Register
» Articles » PMID: 37073574

Sodium-glucose Co-transporter-2 Inhibitor Use and JAK2 Unmutated Erythrocytosis in 100 Consecutive Cases

Overview
Journal Am J Hematol
Specialty Hematology
Date 2023 Apr 19
PMID 37073574
Authors
Naseema Gangat
Mostafa Abdallah
Natasha Szuber
Antoine Saliba
Hassan Alkhateeb
Aref Al-Kali
Kebede H Begna
Animesh Pardanani
Ayalew Tefferi
Affiliations
Soon will be listed here.
Citing Articles

Prevalence and predictive factors of testosterone-induced erythrocytosis: a retrospective single center study.

Neidhart A, von Wyl V, Kaslin B, Henzen C, Fischli S Front Endocrinol (Lausanne). 2025; 15:1496906.

PMID: 39882268 PMC: 11774685. DOI: 10.3389/fendo.2024.1496906.

Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond.

Camilli M, Viscovo M, Maggio L, Bonanni A, Torre I, Pellegrino C Basic Res Cardiol. 2024; 120(1):241-262.

PMID: 38935171 PMC: 11790819. DOI: 10.1007/s00395-024-01059-9.

Myeloproliferative Neoplasms and Sodium-Glucose Co-Transporter-2 Inhibitors: A Case Series.

Patir P, Cerci K, Kurtoglu E Turk J Haematol. 2024; 41(2):130-132.

PMID: 38556957 PMC: 11589262. DOI: 10.4274/tjh.galenos.2024.2024.0050.

Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.

Krecak I, Verstovsek S, Lucijanic M Ann Hematol. 2023; 103(5):1513-1523.

PMID: 37665349 DOI: 10.1007/s00277-023-05426-9.